Impact of Neutropenia on the Effectiveness of Artemisinin-Based Combination Therapy in Pregnant Women in Mali - Scorecard - MDSpire

Impact of Neutropenia on the Effectiveness of Artemisinin-Based Combination Therapy in Pregnant Women in Mali

  • By

  • Moussa Djimde

  • Charles Arama

  • Hamadoun Diakité

  • Mohamed Keita

  • Bouréma Koné

  • Bréhima Tembely

  • Mamadou D. Samaké

  • Balla Bagayoko

  • Mohamed B. Traoré

  • Japhet Kabalu Tshiongo

  • Noluthando Ntlapo

  • Alassane Dicko

  • Michel Vaillant

  • Petra F. Mens

  • Henk D. F. H. Schallig

  • Kassoum Kayentao

  • January 27, 2026

  • 0 min

Share

Clinical Scorecard: Impact of Neutropenia on the Effectiveness of Artemisinin-Based Combination Therapy in Pregnant Women in Mali

At a Glance

CategoryDetail
ConditionMalaria during pregnancy
Key MechanismsReduced immunity in pregnant women increases vulnerability to malaria infection and complications such as anaemia and low birth weight.
Target PopulationPregnant women with microscopically confirmed Plasmodium falciparum infection in Mali.
Care SettingCommunity health centers in San Health District, Mali.

Key Highlights

  • Malaria in pregnancy significantly increases maternal and infant mortality risks.
  • Neutropenia may affect the efficacy of artemisinin-based combination therapies (ACTs).
  • The study evaluates three ACTs: artemether-lumefantrine, dihydroartemisinin-piperaquine, and pyronaridine-artesunate.

Guideline-Based Recommendations

Diagnosis

  • Microscopic confirmation of Plasmodium falciparum infection.

Management

  • Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) and use of insecticide-treated nets (ITNs).
  • Treatment of clinical malaria with ACTs.

Monitoring & Follow-up

  • Regular follow-up on treatment response and neutrophil dynamics.

Risks

  • Increased risk of anaemia and low birth weight associated with malaria during pregnancy.

Patient & Prescribing Data

Pregnant women aged 15 years and older, with gestational age ≥ 16 weeks and < 37 weeks.

ACTs administered based on weight and specific regimens for each drug.

Clinical Best Practices

  • Ensure adherence to study requirements and informed consent.
  • Monitor for complications such as anaemia and low birth weight in treated patients.

References

Original Source(s)

Related Content